Cardiovascular/Metabolic clinical trials

Charting the Path to Heart Health: Advancing Cardiovascular and Metabolic Clinical Trials

Geistek Pharmaceuticals is at the forefront of cardiovascular and metabolic research, driving innovation in the field. We understand the significant impact of cardiovascular and metabolic diseases on global health, and our mission is to discover and develop effective drugs and devices to address these critical medical needs.

With years of experience and a dedicated team of experts, Geistek Pharmaceuticals is committed to conducting comprehensive clinical trials across a range of cardiovascular and metabolic indications. Our focus areas include heart failure, lipid disorders, diabetes, renal insufficiency and transplant, arrhythmia, and rare diseases. Through rigorous research and development, we strive to improve patient outcomes and contribute to the advancement of medical science.

Our approach is rooted in data-driven strategies that optimize timelines and resources throughout the drug development process. We work closely with healthcare professionals, researchers, and regulatory authorities to ensure the highest standards of quality and compliance in our clinical studies.

At Geistek Pharmaceuticals, we recognize the complexity of cardiovascular and metabolic research and the need for specialized expertise. Our multidisciplinary team of professionals, including clinical researchers, scientists, and medical advisors, brings together diverse perspectives to drive innovation and overcome challenges. We collaborate with renowned experts and investigators worldwide to foster a collaborative environment that leads to groundbreaking discoveries.

By leveraging our extensive knowledge and resources, Geistek Pharmaceuticals is dedicated to advancing the understanding of cardiovascular and metabolic diseases. Through our unwavering commitment to excellence in research and development, we aim to improve the lives of patients and contribute to a healthier future for all.

Latest news


INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it

Leer más »

Contact us